CARL is putting up strong growth and a consistent earnings-beat streak, but quality sits below the engine's floor with ongoing cash burn, the stock has already reached its analyst target with a negative asymmetry reading, and momentum looks overbought against weak technical support.
Thesis pillars
- Strong Revenue Growth Leader→Stable
- Consistent Earnings Beats Catalyst↓Deteriorating
- Quality Below Floor Rule Of 40 Fail→Stable
- +2 more pillars — see the Why tab for full reasoning
Carlsmed, Inc. (CARL) Stock Analysis
Healthcare · Health Information Services
Sell if holding. Engine safety override at $14.73: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum.
Carlsmed markets the aprevo Technology Platform, an AI-enabled personalized spine-surgery system pairing custom-fit interbody implants with digital surgical planning for lumbar and (since December 2025) cervical fusion. It earns revenue from implant kit sales reimbursed by... Read more
Sell if holding. Engine safety override at $14.73: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
About Carlsmed, Inc.
About Carlsmed, Inc.
Carlsmed's aprevo Technology Platform combines AI-enabled digital surgical planning with patient-specific interbody implants for lumbar and cervical spine fusion, addressing an estimated $13.4 billion U.S. lumbar and $6 billion U.S. cervical total addressable market. The FDA cleared aprevo lumbar implants via the 510(k) pathway in December 2020 and cervical implants in November 2024, and as of December 31, 2025 the company had 253 surgeon users, up from 152 a year earlier, out of an estimated 4,000 addressable U.S. spine surgeons.
Carlsmed earns revenue by selling aprevo surgical kits — personalized interbody implants and single-use instruments matched to each patient's imaging-derived anatomy — with lumbar procedures reimbursed by Medicare, Medicare Advantage, and commercial payors under premium-paying MS-DRG codes relative to stock-implant procedures. In August 2025, CMS finalized new X-codes and a New Technology Add-on Payment of up to $21,125 per qualifying inpatient cervical spine fusion procedure, effective October 1, 2025, ahead of Carlsmed's December 2025 commercial launch of its cervical platform and corra Cervical Plating System. Because each implant is manufactured to order for an individual patient's anatomy, Carlsmed relies on a limited number of contract manufacturing organizations (CMOs) for the manufacture, treatment, sterilization, packaging, and distribution of its products, an on-demand, customized model the company describes as expensive and time-consuming to manage against variable surgical demand.
Show full overview
Carlsmed's structural exposure is concentrated in its manufacturing supply chain rather than in a single payor or geography: because each aprevo implant is custom-built to a specific patient's pathology, the company cannot simply hold finished-goods inventory as a buffer, and it says reliance on a limited number of CMOs for manufacture, sterilization, packaging, and distribution increases the risk that it will not have sufficient product quantities, or at an acceptable cost, if a CMO cannot meet demand on a timely basis. That dynamic is sharper for Carlsmed than for a stock-implant competitor, since surgeons and hospitals facing a CMO-driven delay could simply switch to a competitor's off-the-shelf implant instead of waiting.
See also: Healthcare · Health Information Services
From Carlsmed, Inc.'s most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-09-14Recent Developments — Carlsmed, Inc.
Latest news
- NEWS Carlsmed Announces Promotion Of Jeff Bertolini To COO, Effective Immediately — benzinga Sep 8, 2026 positive
Generated 2026-09-14T07:47:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -57.4%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.73: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $13.70. Score 6.0/10, moderate confidence.
Take-profit target: $16.70 (+13.4% upside). Prior stop was $13.70. Stop-loss: $13.70.
Quality below floor (3.2 < 4.0).
Carlsmed, Inc. trades at a P/E of N/A (forward -10.7). TrendMatrix value score: 6.0/10. Verdict: Sell.
11 analysts cover CARL with a consensus score of 4.3/5. Average price target: $19.
What does Carlsmed, Inc. do?Carlsmed markets the aprevo Technology Platform, an AI-enabled personalized spine-surgery system pairing custom-fit...
Carlsmed markets the aprevo Technology Platform, an AI-enabled personalized spine-surgery system pairing custom-fit interbody implants with digital surgical planning for lumbar and (since December 2025) cervical fusion. It earns revenue from implant kit sales reimbursed by Medicare and commercial payors, had 253 surgeon users as of December 2025 versus roughly 4,000 addressable U.S. spine surgeons, and relies on a limited number of CMOs to manufacture its implants.